Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).
Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, Baumal C, Holekamp N, Tadayoni R, Kumar N, Parachuri N, Kuppermann BD; International Retina Biosimilar Study Group (Inter BIOS Group); International Retina Biosimilar Study Group (Inter BIOS Group); Bandello F, Querques G, Loewenstein A, Özdek Ş, Rezai K, Laurent K, Bilgic A, Lanzetta P, Zur D, Yannuzzi N, Corradetti G, Kaiser P, Hilely A, Boyer D, Rachitskaya A, Chakravarthy U, Wintergerst M, Sarao V, Parolini B, Mruthyunjaya P, Nguyen QD, Do D, Keane PA, Hassan T, Sridhar J, Eichenbaum D, Grewal D, Splitzer M. Sharma A, et al. Among authors: kuppermann bd. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):851-859. doi: 10.1080/14712598.2023.2176218. Epub 2023 Feb 19. Expert Opin Biol Ther. 2023. PMID: 36726203
Immunogenicity: Clouding the Future of Intravitreal Therapy.
Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD. Sharma A, et al. Among authors: kuppermann bd. Ocul Immunol Inflamm. 2023 Nov;31(9):1746-1749. doi: 10.1080/09273948.2022.2139273. Epub 2022 Nov 4. Ocul Immunol Inflamm. 2023. PMID: 36332149 No abstract available.
Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?
Sharma A, Loewenstein A, Parachuri N, Kumar N, Rasal A, Bandello F, Kuppermann BD. Sharma A, et al. Among authors: kuppermann bd. Eye (Lond). 2024 Feb;38(2):244-245. doi: 10.1038/s41433-023-02698-3. Epub 2023 Aug 30. Eye (Lond). 2024. PMID: 37648725 No abstract available.
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Aflibercept biosimilars - update on the development progress.
Sharma A, Loewenstein A, Kumar N, Parachuri N, Bandello F, Kuppermann BD. Sharma A, et al. Among authors: kuppermann bd. Eye (Lond). 2024 Apr;38(5):824-825. doi: 10.1038/s41433-023-02813-4. Epub 2023 Nov 4. Eye (Lond). 2024. PMID: 37925561 No abstract available.
Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases.
Sharma A, Loewenstein A, Parachuri N, Kumar N, Kuppermann BD. Sharma A, et al. Among authors: kuppermann bd. J Vitreoretin Dis. 2023 Sep 29;7(6):474-476. doi: 10.1177/24741264231202080. eCollection 2023 Nov-Dec. J Vitreoretin Dis. 2023. PMID: 37974924 No abstract available.
256 results